Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

计划入组 225 人 · 首次发布于 2023 年 2 月 17 日

S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP

计划入组 60 人 · 首次发布于 2024 年 1 月 3 日

Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

计划入组 126 人 · 首次发布于 2023 年 6 月 2 日

Tenvie Therapeutics Initiates First-in-Human Trial of CNS-Penetrant NLRP3 Inhibitor TNV262 for Obesity and Cardiovascular Disease

Tango Therapeutics Initiates Phase 1/2 Trial of TNG462 for MTAP-Deleted Solid Tumors

Tango Therapeutics' PRMT5 Inhibitor TNG462 Shows Promise in Early Trials, Combination Studies Planned